Targeted next-generation sequencing of <i>Mycobacterium tuberculosis</i> from patient samples: lessons learned from high drug-resistant burden clinical settings in Bangladesh-Reference-Cited by-同舟云学术

Targeted next-generation sequencing of Mycobacterium tuberculosis from patient samples: lessons learned from high drug-resistant burden clinical settings in Bangladesh

Published:2024-08-26 Issue:1 Volume:13 Page:
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Uddin Mohammad Khaja Mafij¹,Cabibbe Andrea Maurizio²,Nasrin Rumana¹,Ghodousi Arash²,Nobel Fahim Alam¹,Rahman S. M. Mazidur¹,Ahmed Shahriar¹,Ather Md. Fahim¹,Razzaque S. M. Abdur³,Raihan Md. Abu⁴,Modak Pronab Kumar⁵,Berland Jean Luc⁶,Gemert Wayne Van⁷,Mohsin Sardar Munim Ibna⁸,Cirillo Daniela Maria²,Banu Sayera¹

Affiliation:

1. Infectious Diseases Division, icddr,b, Dhaka, Bangladesh

2. Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

3. National Institute of Disease of the Chest and Hospital, Dhaka, Bangladesh

4. 250 bed TB Hospital, Dhaka, Bangladesh

5. National Tuberculosis Control Programme, Bangladesh

6. Fondation Merieux, Lyon, France

7. Stop TB Partnership, Switzerland

8. Office of Population, Health, and Nutrition, U.S. Agency for International Development (USAID), Bangladesh

Funder

United States Agency for International Development (USAID) through the Stop TB Partnership/ the United Nations Office for Project Services

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2024.2392656

Reference43 articles.

1. Viney K Linh NN Gegia M et al. New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization. Eur Respiratory Soc; 2021.

2. Report WGT. Global Tuberculosis Report 2023; 2023.

3. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment 2022 update. World Health Organization; 2022.

4. Lifescience H. GenoType MTBDRplus VER 2.0: Molecular genetic assay for identification of the M. tuberculosis complex and its resistance to rifampicin and isoniazid from clinical specimens and cultivated samples. Nehren: Hain Lifescience GmbH; 2012.

5. Evaluation of Genotype MTBDRsl Assay to Detect Drug Resistance Associated with Fluoroquinolones, Aminoglycosides and Ethambutol on Clinical Sediments